Accepted at 8:36 p.m. Oct, 23, 2023 by Ahmed7
Bulk Suggestion Bulk ID: zarathustra/10.21.23-07:06PM
Author: zarathustra
Co-authors: Cameron
Related Note: 1506457932361
Rationale for change

per AMBOSS, Nirsevimab is now preferred over Palivizumab (approved by FDA, July 2023)
Source: AMBOSS - https://www.amboss.com/us/knowledge/bronchiolitis/

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid








Sketchy


Sketchy 2
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo

OME

Additional Resources
Empty field
One by one
Empty field
#PANCE::EOR::PEDS #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step1_v12::#AMBOSS::FjagXk #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Infectious_Disease::Pneumonia #AK_Step1_v12::#FirstAid::03_Microbiology::05_Virology::15_Paramyxoviruses #AK_Original_Decks::Step_1::Lolnotacop::Bugs #AK_Step1_v12::#SketchyMicro::03_Viruses::04_Retired_Lessons::09_Measles_virus,_mumps_virus,_respiratory_syncytial_virus,_parainfluenza_virus_(Paramyxoviridae)_[Retired_Video] #AK_Step1_v12::#Physeo::06_Micro::05_Viruses::30_Respiratory_Syncytial_Virus_(RSV)_&_Human_Metapneumovirus_(hPMV) #AK_Step1_v12::#FirstAid::03_Microbiology::05_Virology::09_RNA_viruses #PANCE::PULM::infectious_disorders #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::*Palivizumab #PANCE::EOR::IM #AK_Step1_v12::#Bootcamp::Microbiology::29_Negative-sense_RNA_Viruses::05_Respiratory_Syncytial_Virus #AK_Step1_v12::#AMBOSS::Xaa9QQ #AK_Step1_v12::#B&B::18_Pulm::03_Other_Pulmonary_Topics::01_Pneumonia::Extra !AK_UpdateTags::Step1decks::Lolnotacop::Bugs #AK_Step1_v12::#SketchyMicro::03_Viruses::02_RNA_(-)_Sense::03_Respiratory_Syncytial_Virus_&_Human_Metapneumovirus_(Pneumoviridae)